Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the first randomised, phase III study to compare the safety and efficacy of hyperfractionated versus standard fractionated schedule in this setting
Findings from a population-level cohort study
New indication concerns a combination with platinum‐based chemotherapy for the first‐line treatment of NSCLC expressing PD-L1 in ≥ 1% of tumour cells, with no EGFR, ALK or ROS1 aberrations
Findings from the SAKK 08/16
It is recommended for the treatment of newly diagnosed acute myeloid leukaemia and for the treatment of locally advanced or metastatic cholangiocarcinoma
Findings from a prospective multicentre cohort study
Findings from post hoc subgroup analyses of the ARASENS study
Findings from the PRIME II study
Findings from the KarMMa-3 study
Findings from part A of the CheckMate 914 study
Findings from the CodeBreaK 200 study
Efficacy for the regular approval was evaluated in GARNET study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
